Jerald Hammann v. Adamis Pharmaceuticals Corporation

Court of Chancery of Delaware·Decided August 23, 2023·No. C.A. No. 2021-0506-PAF·Published

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

JERALD HAMMANN, )

)

Plaintiff, )

)

v. )

) C.A. No. 2021-0506-PAF

ADAMIS PHARMACEUTICALS ) CORPORATION, DENNIS J. CARLO, ) RICHARD C. WILLIAMS, HOWARD C. ) BIRNDORF, ROSHAWN A. BLUNT, and ) DAVID J. MARGUGLIO, )

)

Defendants. )

MEMORANDUM OPINION

Date Submitted: May 1, 2023 Date Decided: August 23, 2023

Jerald Hammann, Plaintiff, pro se.

Rolin P. Bissell, James M. Yoch, Jr., Alberto E. Chávez, YOUNG CONAWAY STARGATT & TAYLOR, LLP, Wilmington, Delaware; Michael C. Holmes, Robert P. Ritchie, Jeremy R. Gonzalez, VINSON & ELKINS L.L.P., Dallas, Texas; Attorneys for Defendants.

FIORAVANTI, Vice Chancellor

Plaintiff Jerald Hammann commenced this action in June 2021, several weeks after Adamis Pharmaceutical Corporation (“Adamis” or the “Company”) rejected his director nominations and stockholder proposals for consideration at the 2021 annual meeting of stockholders. The Company rejected the nominations and proposals because they were delivered after the deadline provided in the Company’s advance notice bylaw. The court denied Hammann’s application to enjoin the 2021 annual meeting, but agreed to hold an expedited trial on his colorable claim under Schnell v. Chris-Craft Industries, Inc., 285 A.2d 437 (Del. 1985), alleging that the Company had inequitably scheduled the meeting and buried its announcement in an annual report with the purpose of thwarting Hammann’s efforts. The court suggested a trial in September 2021 and noted that if Hammann were to prevail, the court could either require Adamis to conduct a new 2021 annual meeting that would include Hammann’s slate and proposals or, alternatively, compel the Company to include Hammann’s slate and proposals on the ballot for the 2022 annual meeting.

After obtaining expedited proceedings and an opportunity for a prompt trial, Hammann did not press his case. He delayed in responding to the defendants’ scheduling proposals and never presented a schedule to the court. Then, starting in March 2022, Hammann filed serial motions to enjoin Adamis and its directors from filling vacancies and convening the 2022 annual meeting. By that time, Hammann was free to submit his proposals and nominees for election at the 2022 meeting, but

for unexplained reasons, he chose not to do so. Hammann also sought to amend and supplement his complaint. The court denied Hammann’s injunction applications, but permitted him to amend his complaint. Due to Plaintiff’s torpor, the court declined a last-minute bid to bifurcate the case and to hold a trial on Hammann’s Schnell claim in advance of the fast-approaching 2022 annual meeting.

On March 16, 2023, the court held a trial on a paper record and heard argument on the defendants’ motions to dismiss and for summary judgment. Thereafter, Hammann filed a second motion for sanctions, and the defendants filed a motion to compel Hammann to comply with an earlier fee-shifting order. In this post-trial opinion, the court concludes that Hammann’s claims are largely moot and otherwise do not establish damages or a right to other relief. 1

1 The court will address the remaining motions for sanctions and contempt in a separate order.

I. BACKGROUND These are the facts as the court finds them after trial.2

A. Parties Jerald Hammann is an investor and activist stockholder who resides in Minnesota. He is no stranger to litigation in Delaware and beyond, and he frequently represents himself. 3

2 After being identified initially, individuals are referenced herein by their surnames without regard to formal titles such as “Dr.” No disrespect is intended. Unless otherwise indicated, references to the parties’ briefs refer to the parties’ pretrial briefs. Citations in the form “PX” refer to the exhibits attached to the Hammann affidavits, as attached to Plaintiff’s opening and reply pretrial briefs. Dkts. 107–109, 123. References to “Hammann Aff.” refer to the Affidavit of Jerald Hammann re: Facts Supporting Claims filed in tandem with Plaintiff’s Opening Pretrial Brief. Dkt. 109. Citations in the form “DX” refer to the exhibits attached to Defendants’ pretrial answering brief. Dkts. 119– 120. Facts drawn from the parties’ Pre-Trial Stipulation and Order are cited as “PTO ¶ #.” Dkt. 106. 3 See Hammann v. CytRx Corp., C.A. No. 2021-0676-PAF (Del. Ch.) (appearing pro se and seeking a temporary restraining order and expedited proceedings); Hammann v. LadRx Corp., C.A. No. 2022-1101-PAF (Del. Ch.) (appearing pro se and seeking specific performance); see also Hammann v. Deyo, 2010 WL 154212 (Minn. Ct. App. Jan. 19, 2010); Hammann v. Falls/Pinnacle, LLC, 562 U.S. 1198 (2011); Hammann v. Falls/Pinnacle, LLC, 562 U.S. 1272 (2011); Hammann v. Wells Fargo Bank, N.A., 141 S.Ct. 368 (2020); Hammann v. 1-800 Ideas, Inc., 690 F. App’x. 956 (9th Cir. 2017); Hammann v. Schwan’s Sales Enters., Inc., 2004 WL 1049170 (Minn. Ct. App. May 11, 2004); Hammann v. Sexton Lofts, LLC, 136 S.Ct. 2023 (2016); Hammann v. 1-800 Ideas, Inc., 138 S.Ct. 2609 (2018); Hammann v. Wells Fargo Bank, N.A., 138 S.Ct. 482 (2017); Streambend Props. II, LLC v. Ivy Tower Minneapolis, LLC, 577 U.S. 808 (2015); Streambend Props., LLC v. The Carlyle Condos, LLC, 2010 WL 11534596 (D. Minn. Aug. 3, 2010); Hammann v. Turnstone Calhoun L.L.C., 2008 WL 2885800 (Minn. Ct. App. July 29, 2008); Streambend Props. II, LLC v. Ivy Tower Minneapolis, LLC, 2017 WL 66381 (D. Minn. Jan. 6, 2017), aff’d, 701 F. App’x 544 (8th Cir. 2017); Streambend Props. II, LLC v. Ivy Tower Minneapolis LLC, 2019 WL 2332409 (Minn. Ct. App. June 3, 2019), cert. denied, 140 S.Ct. 1118 (2020). In one action, Hammann was adjudicated as a

A few years ago, Hammann developed a business model of approaching struggling biotechnology or biopharmaceutical companies to propose reforms and a consulting arrangement for himself. Should the company decline Hammann’s modest proposal, he floats the prospect of running a proxy contest. His business model has, in some respects, proved lucrative. For example, in early 2020, Hammann initiated a proxy contest against CytRx Corporation (“CytRx”). 4 CytRx entered into a “Cooperation Agreement” with Hammann, under which he agreed to terminate the proxy contest for payment of $275,000 and certain corporate reforms.5 In January 2021, Hammann approached Advaxis, Inc. (“Advaxis”). After Hammann mentioned a possible proxy contest, Advaxis promptly retained Hammann’s private consulting firm for $150,000 and other contingent payments.6 Hammann and his consulting firm were not asked to provide any consulting services after they executed the agreement.7 After inking his deal with Advaxis, Hammann

“frivolous litigant” under the Minnesota practice rules, resulting in the imposition of preconditions before he could file new claims. See Deyo, 2010 WL 154212, at *7–8 (affirming trial court ruling that Hammann was a frivolous litigant). A frivolous litigant is defined under the Minnesota rules as one “‘who, after a claim has been finally determined against the person, repeatedly relitigates or attempts to relitigate either’ finally-determined matters or one who maintains claims not well-grounded in law.” Id. at *7 (quoting Minn. Gen. R. Pract. 9.06(b)(1), (3)). 4 PTO ¶ 10.

5 Id. ¶ 11; DX 1 at 135:1–12 (Hammann).

6 PTO ¶¶ 12–13; DX 1 at 121:2–20 (Hammann).

7 DX 1 at 128:25–129:17 (Hammann).

immediately set his sights on Adamis, a Delaware corporation focused on developing and commercializing products for therapeutic use. At that time, the Adamis board consisted of Dennis J. Carlo, Richard C. Williams, Howard C. Birndorf, Roshawn A. Blunt, and David J. Marguglio (together with Adamis, the “Defendants”). Carlo also served as the Company’s President and Chief Executive Officer. Marguglio was a Senior Vice President and Chief Business Officer.

B. Hammann Approaches Adamis On February 9, 2021, eight days after the public announcement of the Advaxis

Free access — add to your briefcase to read the full text and ask questions with AI

Jerald Hammann v. Adamis Pharmaceuticals Corporation, (Del. Ct. App. 2023).

Jerald Hammann v. Adamis Pharmaceuticals Corporation (Jerald Hammann v. Adamis Pharmaceuticals Corporation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Maldonado v. Flynn
597 F.2d 789 (Second Circuit, 1979)
Lee v. Schmidt-Wenzel
766 F.2d 1387 (Ninth Circuit, 1985)
Stearn v. Koch
628 A.2d 44 (Supreme Court of Delaware, 1993)
Loudon v. Archer-Daniels-Midland Co.
700 A.2d 135 (Supreme Court of Delaware, 1997)
Sanders v. Thrall Car Manufacturing Co.
582 F. Supp. 945 (S.D. New York, 1983)
Millenco L.P. v. meVC Draper Fisher Jurvetson Fund I, Inc.
824 A.2d 11 (Court of Chancery of Delaware, 2002)
General Motors Corp. v. New Castle County
701 A.2d 819 (Supreme Court of Delaware, 1997)
Adams v. Jankouskas
452 A.2d 148 (Supreme Court of Delaware, 1982)
Glazer v. Pasternak
693 A.2d 319 (Supreme Court of Delaware, 1997)
Stroud v. Milliken Entersprises, Inc.
552 A.2d 476 (Supreme Court of Delaware, 1989)
NAMA Holdings, LLC v. Related World Market Center, LLC
922 A.2d 417 (Court of Chancery of Delaware, 2007)
Rollins International, Inc. v. International Hydronics Corp.
303 A.2d 660 (Supreme Court of Delaware, 1973)
Johnston v. Arbitrium (Cayman Islands) Handels AG
720 A.2d 542 (Supreme Court of Delaware, 1998)
Goodrich v. E.F. Hutton Group, Inc.
681 A.2d 1039 (Supreme Court of Delaware, 1996)
Spence v. Funk
396 A.2d 967 (Supreme Court of Delaware, 1978)
Motorola, Inc. v. Amkor Technology, Inc.
958 A.2d 852 (Supreme Court of Delaware, 2008)
Schnell v. Chris-Craft Industries, Inc.
285 A.2d 437 (Supreme Court of Delaware, 1971)
In Re JP Morgan Chase & Co.
906 A.2d 766 (Supreme Court of Delaware, 2006)
Smillie v. Park Chemical Co.
466 F. Supp. 572 (E.D. Michigan, 1979)